HOME>News Release

News Release

  • Mitsubishi Tanabe Pharma
  • Former Mitsubishi Pharma
  • RSS
  • About RSS


September 20
Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion Ophthalmic Solution 0.05% and Alesion LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co., Ltd.PDFNEW
September 17
Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in BrazilPDF
September 4
Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy productPDF
August 28
The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s diseasePDF
August 8
PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US INDPDF
August 8
Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)PDF
August 7
NMPA approved Japan-originated ALS treatment Edaravone in ChinaPDF
August 6
Commencement of R&D of Gene Therapy Product for Hemophilia BPDF
July 29
Announcement of FY2019 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 23
Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemiaPDF
May 30
Withdrawal of Marketing Authorization Application of edaravone for ALS in the European UnionPDF
May 29
Launch of SIMPONI Subcutaneous Injection 50mg AutoinjectorPDF
May 10
Announcement of Financial Results for FY2018
⇒R&D Pipeline "State of New Product Development"
April 26
Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseasesPDF
April 24
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019PDF
April 15
For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in ChinaPDF
April 11
Notice Regarding Reorganization of Research, Production, and Technology BasesPDF
March 28
The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institutionPDF
March 26
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb IschemiaPDF
March 20
Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative OfficePDF
March 12
Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKDPDF
February 28
Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA in ChinaPDF
February 20
Mitsubishi Tanabe Pharma Received Notice of Request for ArbitrationPDF
February 14
FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid TumorsPDF
February 12
First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care AppPDF
February 6
Swissmedic approves RADICAVA, Japan-originated ALS treatmentPDF
February 4
Announcement of FY2018 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 4
Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.PDF


December 11
HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research CollaborationPDF
December 10
Conduct a study to identify and measure specific biomarkers in ALS - we will strive to deliver a beneficial therapy option to patients -PDF
November 19
Notice Regarding Revision of Medium-Term Management Plan 16-20: Open Up the FuturePDF
November 15
Mitsubishi Tanabe Pharma to present New data on Investigational Oral Suspension of Edaravone for ALS at 29th International Symposium on ALS/MNDPDF
October 30
Announcement of FY2018 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
October 22
Strategic Research Collaboration for the Development of Innovative Antibody Drug to Treat Autoimmune DiseasesPDF
October 9
Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound LibraryPDF
October 5
For the ALS patients in Canada, we hope to deliver Japan-originated ALS treatment ―Health Canada approves RADICAVA (edaravone) for the treatment of ALSPDF
September 26
Company name changes of our oversea subsidiariesPDF
September 18
Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific IndexPDF
July 30
Announcement of FY2018 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 27
Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic ProtoporphyriaPDF
July 19
Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―PDF
July 2
Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -PDF
July 2
Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -PDF
June 28
Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. update co-promotion framework for STELARA, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA to treat adults with Crohn’s disease in JapanPDF
June 14
TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in TaiwanPDF
May 30
Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companiesPDF
May 28
For the ALS patients in the world,we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALSPDF
May 18
Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize fromthe Japan Chemical Industry Association (JCIA)PDF
May 9
Announcement of Financial Results for FY2017
⇒R&D Pipeline "State of New Product Development"
April 10
Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life SciencePDF
April 10
To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in CanadaPDF
March 26
Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug DevelopmentPDF
March 6
Name Change of our Singapore SubsidiaryPDF
March 1
Mitsubishi Tanabe Pharma Group started marketing CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus in TaiwanPDF
February 28
Valixa Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrupPDF
February 5
Announcement of FY2017 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
January 23
Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatmentPDF
January 16
Approval in China Received for Additional Novastan Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical MarketPDF
January 11
Launch of "KREMEZIN Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―PDF

News Release

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide